COMPUTATIONAL BIO
From Wet-Lab Alpha to GMP Scale: Avoiding the Series A Valley of Death
AUTHORING PARTNER
Dr. Helena Lindholm
PARTNER TITLE
General Partner
CORE THESIS METRIC
10,000x Assay Loop
EXECUTIVE INVESTMENT THESIS
How computational biology founders turn academic Nature papers into repeatable unit economics before raising an institutional Series A.
ARCHITECTURAL & MARKET ANALYSIS
Series A investors no longer fund pure in-silico target discovery promises. The breakout bio platforms own the closed-loop experimental assay—generating proprietary failure-and-binding datasets no public model can scrape.
WHAT WE LOOK FOR AT PRE-SEED & SEED
Proprietary wet-lab data generation loop · Unit cost per validated assay dropping >50% YoY · At least 2 paid biopharma or industrial pilot milestones.
01 // APEX VENTURES
DeepTech Seed & Series A
$420M Fund IV leading $1.5M–$12M checks in AI silicon, robotics, computational bio, and grid infrastructure.
02 // CAPITAL & PORTFOLIO
Mandate & Ledger
Clean 1x non-participating preferred governance plus $350K non-dilutive H100 compute access.
03 // PARTNERSHIP
Bench & Research
Every memo read directly by former-founder General Partners in San Francisco, New York, and Zurich.
04 // GOVERNANCE & DOCS
Disclosures & Manual
SEC/Advisers Act non-solicitation notices, founder confidentiality, and 12-station owner manual.
© 2026 APEX VENTURES MANAGEMENT LLC · SAN FRANCISCO · NEW YORK · ZURICH · NOT AN OFFER TO SELL SECURITIES OR LP INTERESTS.
FUND IV DEPLOYING // 48-HR GP REVIEW SLA